In 2022, two new classifications of myeloid neoplasms and acute leukemias were published: the 5th edition WHO Classification (WHO-HAEM5) and the International Consensus Classification (ICC). As with prior classifications, the WHO-HAEM5 and ICC made updates to the prior classification (revised 4th edition WHO Classification, WHO-HAEM4R) based on a consensus of groups of experts, who examined new evidence. Both WHO-HAEM5 and ICC introduced several new disease entities that are based predominantly on genetic features, superseding prior morphologic definitions. While it is encouraging that two groups independently came to similar conclusions in updating the classification of myeloid neoplasms and acute leukemias, there are several divergences in how WHO-HAEM5 and ICC define specific entities as well as differences in nomenclature of certain diseases. In this review, we highlight the similarities and differences between the WHO-HAEM5 and ICC handling of myeloid neoplasms and acute leukemias and present a practical approach to diagnosing and classifying these diseases in this current era of two divergent classification guidelines.

中文翻译：

---

髓系肿瘤和急性白血病分类的实用方法：WHO 和 ICC


2022 年，发布了髓系肿瘤和急性白血病的两种新分类：第 5 版 WHO 分类 （WHO-HAEM5） 和国际共识分类 （ICC）。与以前的分类一样，WHO-HAEM5 和 ICC 根据审查新证据的专家组的共识，对之前的分类（修订后的第 4 版 WHO 分类，WHO-HAEM4R）进行了更新。WHO-HAEM5 和 ICC 都引入了几种主要基于遗传特征的新疾病实体，取代了先前的形态学定义。虽然令人鼓舞的是，两个小组在更新髓系肿瘤和急性白血病的分类方面独立得出了相似的结论，但 WHO-HAEM5 和 ICC 如何定义特定实体以及某些疾病的命名存在差异。在这篇综述中，我们强调了 WHO-HAEM5 和 ICC 处理髓系肿瘤和急性白血病之间的异同，并提出了在当前两个不同分类指南的时代诊断和分类这些疾病的实用方法。